Although many of the top 15 highest paid biopharma CEOs received raises in 2021, the year was peppered with high profile resignations. For example, the 13th place went to former Biogen CEO Michel Vounatsos, whose resignation was announced in May. Clay Siegall, former CEO of Seagen, earned nearly $19 million in 2021, but resigned this May due to his arrest for domestic violence. The roster was notably filled by men only.
According to Fierce Healthcare, “But that’s not to say female biopharma execs haven’t been coming up in recent months. GSK’s Emma Walmsley, for example, scored a 17% pay rise last year, bagging 8.2 million pounds sterling ($10.88 million). And Vertex CEO Reshma Kewalramani came just short of making the cut in 2021 with full-year compensation of $15.19 million, which would have landed her the No. 16 spot beneath Merck’s departed CEO Frazier.”
To learn more, click here.
(Source: June 27th, 2022)
